Edgewise Therapeutics Inc. (EWTX)
NASDAQ: EWTX · Pharmaceutical Preparations · Boulder, CO
Our rating: Positive
Call changed from Neutral to Positive at $45.04, moderate conviction, November 6, 2026.
Breaks if: The Positive call breaks if any lead program produces a pivotal-trial failure or receives a complete-response letter within the next 12 months, or if two consecutive quarterly filings show cash burn accelerating beyond $50M per quarter with no accompanying financing close — implying runway contracting below eight quarters and forcing dilutive capital raises. On price terms, a sustained drawdown of 35% or more from $45.04 within the next 12 months would signal the market has repriced pipeline risk toward zero and would require a full reassessment of the thesis.
Key figures
| Market value | $4.4B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | $1.0B |
| Free cash flow, last 12 months | −$202M |
| Price to earnings | 4.3× |
| Free cash flow yield | −4.6% |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | 92.1% |
| Beta to the S&P 500 | 1.29 |
| Volatility, annualized | 78.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | n/a | n/a | $9.65 | −$78M |
| June 30, 2026 | n/a | n/a | $-0.53 | −$43M |
| March 31, 2026 | n/a | n/a | $-0.46 | −$43M |
| December 31, 2025 | n/a | n/a | $-0.48 | −$39M |
| September 30, 2025 | n/a | n/a | $-0.39 | −$35M |
| June 30, 2025 | n/a | n/a | $-0.34 | −$33M |
| March 31, 2025 | n/a | n/a | $-0.43 | −$38M |
| December 31, 2024 | n/a | n/a | $-0.42 | −$27M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 18%, Gemini 15%, Mistral 8%
- Free cash flow for the quarter is above zero: Claude 12%, Gemini 5%, Mistral 2%
26 ledger entries and 18 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.